This is a summary of the European public assessment report (EPAR) for Spinraza. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Spinraza.
For practical information about using Spinraza, patients should read the package leaflet or contact their doctor or pharmacist.
Spinraza : EPAR - Summary for the public (PDF/78.3 KB)
First published: 21/06/2017
Last updated: 11/01/2018
Spinraza : EPAR - Risk-management-plan summary (PDF/623.24 KB)
First published: 09/10/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Muscular Atrophy, Spinal
|Anatomical therapeutic chemical (ATC) code||
Biogen Netherlands B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
Prins Mauritslaan 13
31/01/2022 Spinraza - EMEA/H/C/004312 - R/0025
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Other nervous system drugs
Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.